Loading…
Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors
A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated ag...
Saved in:
Published in: | Archiv der Pharmazie (Weinheim) 2018-04, Vol.351 (3-4), p.e1700311-n/a |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743 |
---|---|
cites | cdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743 |
container_end_page | n/a |
container_issue | 3-4 |
container_start_page | e1700311 |
container_title | Archiv der Pharmazie (Weinheim) |
container_volume | 351 |
creator | Lamie, Phoebe F. Philoppes, John N. Rárová, Lucie |
description | A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.
A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. |
doi_str_mv | 10.1002/ardp.201700311 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1994362369</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2020969070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</originalsourceid><addsrcrecordid>eNqFkcFuEzEQhi0EoqFw5YgscSlSknps7258rFKgSJGCEEi9rbzr2dSVY4e1N7A98Qi8C2_Ek-CSUiQuHOyZkb75Nfp_Qp4DmwNj_FT3ZjfnDCrGBMADMoGCw0zCQj4kEybKYlZyIY7IkxivWWYYLx6TI64kYxJgQn6cY7QbP6Vx9Okq93FKtTe0scGFjW21o7jXbtDJBk9DR33Yo6Mw5T-_fTdW96PLjcwvDk1MNg0JTZ4a9DejswY95qk4kRevcrVba_RNVvZIDfZ2n2X3GKmOtB1TSOGrbaneoE_x9xXL9WXe4qer9SW1_so2NoU-PiWPOu0iPrurx-TTm9cflxez1frtu-XZataKSmQTkFUVyEIxBpqjFmVXQbMoFkbqouoaBaoCBFOWDRcFF6Yw-UcjoRXNopLimJwcdHd9-DxgTPXWxhad0x7DEGtQSopsb6ky-vIf9DoMvc_X1ZxxpkrFKpap-YFq-xBjj1296-02e1gDq2_jrG_jrO_jzAsv7mSHZovmHv-TXwbUAfhiHY7_kavPPpy__yv-C_dks5k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2020969070</pqid></control><display><type>article</type><title>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Lamie, Phoebe F. ; Philoppes, John N. ; Rárová, Lucie</creator><creatorcontrib>Lamie, Phoebe F. ; Philoppes, John N. ; Rárová, Lucie</creatorcontrib><description>A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.
A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes.</description><identifier>ISSN: 0365-6233</identifier><identifier>EISSN: 1521-4184</identifier><identifier>DOI: 10.1002/ardp.201700311</identifier><identifier>PMID: 29400411</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis ; Anti-Inflammatory Agents, Non-Steroidal - chemistry ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; anti‐inflammatory ; Arachidonate 5-Lipoxygenase - metabolism ; Cell Survival - drug effects ; Cells, Cultured ; Cyclooxygenase 2 - metabolism ; Cyclooxygenase 2 Inhibitors - chemical synthesis ; Cyclooxygenase 2 Inhibitors - chemistry ; Cyclooxygenase 2 Inhibitors - pharmacology ; Cytotoxicity ; diaryl imidazolone derivatives ; Dose-Response Relationship, Drug ; Drug Design ; Humans ; Imidazoles - chemical synthesis ; Imidazoles - chemistry ; Imidazoles - pharmacology ; Lipoxygenase Inhibitors - chemical synthesis ; Lipoxygenase Inhibitors - chemistry ; Lipoxygenase Inhibitors - pharmacology ; Molecular Docking Simulation ; molecular docking study ; Molecular Structure ; Structure-Activity Relationship</subject><ispartof>Archiv der Pharmazie (Weinheim), 2018-04, Vol.351 (3-4), p.e1700311-n/a</ispartof><rights>2018 Deutsche Pharmazeutische Gesellschaft</rights><rights>2018 Deutsche Pharmazeutische Gesellschaft.</rights><rights>2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</citedby><cites>FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</cites><orcidid>0000-0003-2477-4900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29400411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamie, Phoebe F.</creatorcontrib><creatorcontrib>Philoppes, John N.</creatorcontrib><creatorcontrib>Rárová, Lucie</creatorcontrib><title>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</title><title>Archiv der Pharmazie (Weinheim)</title><addtitle>Arch Pharm (Weinheim)</addtitle><description>A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.
A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - chemistry</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>anti‐inflammatory</subject><subject>Arachidonate 5-Lipoxygenase - metabolism</subject><subject>Cell Survival - drug effects</subject><subject>Cells, Cultured</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Cyclooxygenase 2 Inhibitors - chemical synthesis</subject><subject>Cyclooxygenase 2 Inhibitors - chemistry</subject><subject>Cyclooxygenase 2 Inhibitors - pharmacology</subject><subject>Cytotoxicity</subject><subject>diaryl imidazolone derivatives</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Humans</subject><subject>Imidazoles - chemical synthesis</subject><subject>Imidazoles - chemistry</subject><subject>Imidazoles - pharmacology</subject><subject>Lipoxygenase Inhibitors - chemical synthesis</subject><subject>Lipoxygenase Inhibitors - chemistry</subject><subject>Lipoxygenase Inhibitors - pharmacology</subject><subject>Molecular Docking Simulation</subject><subject>molecular docking study</subject><subject>Molecular Structure</subject><subject>Structure-Activity Relationship</subject><issn>0365-6233</issn><issn>1521-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkcFuEzEQhi0EoqFw5YgscSlSknps7258rFKgSJGCEEi9rbzr2dSVY4e1N7A98Qi8C2_Ek-CSUiQuHOyZkb75Nfp_Qp4DmwNj_FT3ZjfnDCrGBMADMoGCw0zCQj4kEybKYlZyIY7IkxivWWYYLx6TI64kYxJgQn6cY7QbP6Vx9Okq93FKtTe0scGFjW21o7jXbtDJBk9DR33Yo6Mw5T-_fTdW96PLjcwvDk1MNg0JTZ4a9DejswY95qk4kRevcrVba_RNVvZIDfZ2n2X3GKmOtB1TSOGrbaneoE_x9xXL9WXe4qer9SW1_so2NoU-PiWPOu0iPrurx-TTm9cflxez1frtu-XZataKSmQTkFUVyEIxBpqjFmVXQbMoFkbqouoaBaoCBFOWDRcFF6Yw-UcjoRXNopLimJwcdHd9-DxgTPXWxhad0x7DEGtQSopsb6ky-vIf9DoMvc_X1ZxxpkrFKpap-YFq-xBjj1296-02e1gDq2_jrG_jrO_jzAsv7mSHZovmHv-TXwbUAfhiHY7_kavPPpy__yv-C_dks5k</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Lamie, Phoebe F.</creator><creator>Philoppes, John N.</creator><creator>Rárová, Lucie</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2477-4900</orcidid></search><sort><creationdate>201804</creationdate><title>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</title><author>Lamie, Phoebe F. ; Philoppes, John N. ; Rárová, Lucie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - chemistry</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>anti‐inflammatory</topic><topic>Arachidonate 5-Lipoxygenase - metabolism</topic><topic>Cell Survival - drug effects</topic><topic>Cells, Cultured</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Cyclooxygenase 2 Inhibitors - chemical synthesis</topic><topic>Cyclooxygenase 2 Inhibitors - chemistry</topic><topic>Cyclooxygenase 2 Inhibitors - pharmacology</topic><topic>Cytotoxicity</topic><topic>diaryl imidazolone derivatives</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Humans</topic><topic>Imidazoles - chemical synthesis</topic><topic>Imidazoles - chemistry</topic><topic>Imidazoles - pharmacology</topic><topic>Lipoxygenase Inhibitors - chemical synthesis</topic><topic>Lipoxygenase Inhibitors - chemistry</topic><topic>Lipoxygenase Inhibitors - pharmacology</topic><topic>Molecular Docking Simulation</topic><topic>molecular docking study</topic><topic>Molecular Structure</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamie, Phoebe F.</creatorcontrib><creatorcontrib>Philoppes, John N.</creatorcontrib><creatorcontrib>Rárová, Lucie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Archiv der Pharmazie (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamie, Phoebe F.</au><au>Philoppes, John N.</au><au>Rárová, Lucie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors</atitle><jtitle>Archiv der Pharmazie (Weinheim)</jtitle><addtitle>Arch Pharm (Weinheim)</addtitle><date>2018-04</date><risdate>2018</risdate><volume>351</volume><issue>3-4</issue><spage>e1700311</spage><epage>n/a</epage><pages>e1700311-n/a</pages><issn>0365-6233</issn><eissn>1521-4184</eissn><abstract>A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1H NMR, DEPT‐Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX‐2 rather than COX‐1, and the IC50 values (0.25–1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX‐2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02–74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4‐chlorobenzoxazole derivative) was found to have dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes. They linked to COX‐2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.
A new series of 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives 4a–l was synthesized and evaluated for their in vitro cytotoxic activities. Assessment of the cyclooxygenase (COX)‐1, COX‐2 and lipoxygenase (LOX) inhibitory activities revealed 4c as the most active compound with dual COX‐2/LOX activity. All the synthesized compounds were docked inside the active site of the COX‐2 and LOX enzymes.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29400411</pmid><doi>10.1002/ardp.201700311</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2477-4900</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0365-6233 |
ispartof | Archiv der Pharmazie (Weinheim), 2018-04, Vol.351 (3-4), p.e1700311-n/a |
issn | 0365-6233 1521-4184 |
language | eng |
recordid | cdi_proquest_miscellaneous_1994362369 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis Anti-Inflammatory Agents, Non-Steroidal - chemistry Anti-Inflammatory Agents, Non-Steroidal - pharmacology anti‐inflammatory Arachidonate 5-Lipoxygenase - metabolism Cell Survival - drug effects Cells, Cultured Cyclooxygenase 2 - metabolism Cyclooxygenase 2 Inhibitors - chemical synthesis Cyclooxygenase 2 Inhibitors - chemistry Cyclooxygenase 2 Inhibitors - pharmacology Cytotoxicity diaryl imidazolone derivatives Dose-Response Relationship, Drug Drug Design Humans Imidazoles - chemical synthesis Imidazoles - chemistry Imidazoles - pharmacology Lipoxygenase Inhibitors - chemical synthesis Lipoxygenase Inhibitors - chemistry Lipoxygenase Inhibitors - pharmacology Molecular Docking Simulation molecular docking study Molecular Structure Structure-Activity Relationship |
title | Design, synthesis, and biological evaluation of novel 1,2‐diaryl‐4‐substituted‐benzylidene‐5(4H)‐imidazolone derivatives as cytotoxic agents and COX‐2/LOX inhibitors |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A49%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20synthesis,%20and%20biological%20evaluation%20of%20novel%201,2%E2%80%90diaryl%E2%80%904%E2%80%90substituted%E2%80%90benzylidene%E2%80%905(4H)%E2%80%90imidazolone%20derivatives%20as%20cytotoxic%20agents%20and%20COX%E2%80%902/LOX%20inhibitors&rft.jtitle=Archiv%20der%20Pharmazie%20(Weinheim)&rft.au=Lamie,%20Phoebe%20F.&rft.date=2018-04&rft.volume=351&rft.issue=3-4&rft.spage=e1700311&rft.epage=n/a&rft.pages=e1700311-n/a&rft.issn=0365-6233&rft.eissn=1521-4184&rft_id=info:doi/10.1002/ardp.201700311&rft_dat=%3Cproquest_cross%3E2020969070%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3731-4e0771459001a2ea36f71b858d4a57fb91971e1d66b23523d5d523ed41c3b8743%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2020969070&rft_id=info:pmid/29400411&rfr_iscdi=true |